Imerslund-Gräsbeck syndrome (IGS) or selective cobalamin malabsorption has been described in humans and dogs. IGS occurs in Border Collies and is inherited as a monogenic autosomal recessive trait in this breed. Using 7 IGS cases and 7 non-affected controls we mapped the causative mutation by genome-wide association and homozygosity mapping to a 3.53 Mb interval on chromosome 2. We re-sequenced the genome of one affected dog at ∼10× coverage and detected 17 non-synonymous variants in the critical interval. Two of these non-synonymous variants were in the cubilin gene (CUBN), which is known to play an essential role in cobalamin uptake from the ileum. We tested these two CUBN variants for association with IGS in larger cohorts of dogs and found that only one of them was perfectly associated with the phenotype. This variant, a single base pair deletion (c.8392delC), is predicted to cause a frameshift and premature stop codon in the CUBN gene. The resulting mutant open reading frame is 821 codons shorter than the wildtype open reading frame (p.Q2798Rfs*3). Interestingly, we observed an additional nonsense mutation in the MRC1 gene encoding the mannose receptor, C type 1, which was in perfect linkage disequilibrium with the CUBN frameshift mutation. Based on our genetic data and the known role of CUBN for cobalamin uptake we conclude that the identified CUBN frameshift mutation is most likely causative for IGS in Border Collies.
Citation: Owczarek-Lipska M, Jagannathan V, Drögemüller C, Lutz S, Glanemann B, Leeb T, et al. (2013) A Frameshift Mutation in the Cubilin Gene (CUBN) in Border Collies with Imerslund-Gräsbeck Syndrome (Selective Cobalamin Malabsorption). PLoS ONE 8(4): e61144. https://doi.org/10.1371/journal.pone.0061144
Editor: Claire Wade, University of Sydney, United States of America
Received: November 29, 2012; Accepted: March 5, 2013; Published: April 16, 2013
Copyright: © 2013 Owczarek-Lipska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded in part by a grant from the Albert-Heim Foundation. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Cobalamin is a member of the B-group, water soluble vitamins. Cobalamin is also known as vitamin B12. The abbreviation B12 covers all forms of cobalamins (i.e. all compounds with a corrin ring structure) and not only cyanocobalamin, which is the vitamin B12 . Higher organisms such as plants or animals are unable to synthesize cobalamin. Mammals rely on either dietary cobalamin or symbiontic microorganisms to obtain this essential compound. Vitamin B12 serves as coenzyme for 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) and methylmalonyl coenzyme A mutase (MUT). Deficiency of cobalamin leads to reduced activity of both of these enzymes resulting in an increase of methylmalonic acid (MMA) and total homocysteine (tHcy). Therefore, measurements of these metabolites allow the assessment of cellular cobalamin availability and are the tests of choice to detect early or mild cobalamin deficiency in humans .
MTR is involved in the synthesis of DNA. Therefore, a lack of cobalamin affects rapidly dividing cells and leads to changes in the hematopoietic system such as megaloblastic anemia. Chronic deficiency of cobalamin also leads to neurological symptoms and irreversible damage of the brain and nervous system .
The uptake of dietary cobalamin in mammals is a complex process requiring several endogenous proteins. In the small intestine the dietary cobalamin (“extrinsic factor”) is bound to a secreted protein, called gastric intrinsic factor (GIF). The uptake of the cobalamin-GIF complex from the intestinal lumen into the body is mediated by a specific membrane protein complex termed cubam receptor , . Cubam consists of two separate protein subunits, amnionless (AMN) and cubilin (CUBN).
Mutations in either the AMN or CUBN genes lead to Imerslund-Gräsbeck syndrome (IGS) or selective cobalamin malabsorption , . IGS in humans is a rare autosomal recessive disorder, which results in megaloblastic anemia, mild proteinuria, failure to thrive, and neurological damage when untreated. IGS can be successfully managed by supplementation with regular doses of cobalamin .
Primary cobalamin absorption disorders have also been reported in several dog breeds including Australian Shepherd Dogs , Beagles , Border Collies –, Giant Schnauzers , and Shar-Peis . Two independent mutations in the AMN gene cause IGS in Australian Shepherd Dogs and Giant Schnauzers, respectively . The molecular defect in the other dog breeds has not yet been reported.
We previously described clinical and laboratory findings in young Border Collies with IGS and established breed-specific reference parameters for serum cobalamin, urine methymalonic acid, and plasma homocysteine concentrations in Border Collies , . The goal of the present study was the identification of the causative mutation for IGS in the Border Collie breed.
We previously described the clinical phenotype of IGS in Border Collies in detail . Briefly, affected dogs were young (median 11.5 months, range 8–42 months) when finally diagnosed. Historical complaints included intermittent diarrhea, inappetence (picky appetite to anorexia) with poor body condition (BCS 2–3/9), and failure to grow. Clinically the marked weakness and small growth were the predominant findings. Additional clinical signs included odynophagia, glossitis, and bradyarrhythmia. Pertinent laboratory abnormalities consisted of mild to moderate normocytic, non-regenerative anemia with evidence of dyserythropoesis (increased numbers of nucleated red blood cells), increased aspartate-aminotransferase activity, and mild proteinuria. All dogs had serum cobalamin levels below the detection limit of the assay, as well as marked methylmalonic aciduria and hyperhomocysteinemia. We achieved full clinical recovery in all dogs with regular parenteral cobalamin supplementation .
Mapping of the Causative Mutation
We genotyped 173,662 evenly spaced SNPs on DNA samples from 7 affected Border Collies and 7 controls. After removing 61,339 markers, which had bad call rates (<90%), were non-informative (MAF <0.05), or showed a strong deviation from Hardy-Weinberg equilibrium in the controls (p<10−5), we retained 112,323 markers for the final genome-wide allelic association study. Three best-associated SNPs in the GWAS had identical raw p-values of 4.6×10−6 (Figure 1A). The corrected p-value after 100,000 permutations was 0.046. The 19 best-associated SNPs with raw p-values of less than 8×10−5 were all located on CFA 2 (Figure 1B). It has to be cautioned that the genomic inflation factor in this analysis was 1.36. This high value indicates sample stratification, which was caused by the use of closely related dogs including one full-sib pair among the cases. As the GWAS results showed an unequivocal signal we did not perform sophisticated corrections for the stratification in our samples.
(A) A genome-wide association study using 7 cases and 7 controls indicates a signal on CFA 2. (B) The detailed view of CFA 2 delineates an associated interval of ∼5 Mb. (C) Homozygosity mapping. Each horizontal bar corresponds to the CFA 2 genotypes of the 7 analyzed cases. Homozygous regions with shared alleles are shown in blue. A shared homozygous interval delineates the exact boundaries of the critical interval from 17,283,880 to 20,818,258 bp (CanFam 3 assembly).
Subsequently, we applied a homozygosity mapping approach to fine-map the region containing the disproportionate dwarfism mutation. We hypothesized that the affected dogs most likely were inbred to one single founder animal. Under this scenario the affected individuals were expected to be identical by descent (IBD) for the causative mutation and flanking chromosomal segments. We analyzed the cases for extended regions of homozygosity with simultaneous allele sharing. Only one genome region, which coincided with the associated interval on CFA 2, fulfilled our search criteria. Here, all 7 affected dogs were homozygous and shared identical alleles over 229 SNP markers corresponding to a ∼3.5 Mb interval. We concluded that the causative mutation should be located in the 3.53 Mb critical interval between the closest heterozygous markers on either side of the homozygous segment (CFA2∶17,283,880–20,818,258, CanFam 3 assembly; Figure 1C).
A total of 33 genes and loci are annotated in the critical interval on CFA 2 (CanFam 3.1, Table S1). In order to obtain a comprehensive overview of all variants in the critical interval we sequenced the whole genome of one affected Border Collie. We collected 127 million 2×100 bp paired-end reads from a shotgun fragment library corresponding to roughly 10× coverage of the genome. We called SNPs and indel variants with respect to the reference genome of a presumably non-affected Boxer. Across the entire genome, we detected 2.5 million homozygous variants (Table 1). Within the critical interval there were 3,173 variants, of which 17 were predicted to be non-synonymous (Table S2). We further compared the genotypes of the affected Border Collie with 12 dog genomes of various breeds that had been sequenced in our laboratory in the course of other ongoing studies. We hypothesized that the mutant allele at the causative variant should be completely absent from all other dog breeds outside Border Collies as the large size of the associated haplotype clearly indicated a relatively young origin of the mutation. Therefore, we considered it unlikely that the mutant allele would have been introgressed into any other breeds outside Border Collies. Among the 17 non-synonymous variants, there were only 3 variants where the affected Border Collie carried the homozygous variant genotype and all other 12 sequenced dogs carried the homozygous wildtype genotype (Table 2).
We genotyped all remaining non-synonymous variants in larger cohorts of dogs (Table 3). Two variants, MRC1:c.2143C>T and CUBN:c.8392delC, were perfectly associated with IGS in a cohort of 200 Border Collies. These variants were absent from more than 300 dogs of other breeds. The MRC1:c.2143C>T variant represents a nonsense mutation and is predicted to truncate more than 50% of the mannose receptor, C type 1 (p.R715*). The CUBN:c.8392delC variant is predicted to result in a frameshift and early premature termination codon in the open reading frame encoding cubilin (p.Q2798Rfs*3; Figure 2).
Electropherograms of a homozygous wildtype, heterozygous, and homozygous mutant dog, respectively, are shown. The position of the deletion is indicated by arrows. The predicted amino acid translation is shown above the sequence. Altered codons in the affected dog are shown in red. The deletion results in an early premature stop codon (p.Q2798Rfs*3).
Using a purely positional approach, we have identified two variants that are perfectly associated with IGS in Border Collies. Both of these variants in the MRC1 and CUBN genes, respectively, lead to premature stop codons and are predicted to completely abolish the function of the encoded proteins. The MRC1 gene encodes the mannose receptor, C type 1, which is expressed on macrophages and endothelial cells of the liver. MRC1 has a presumed role in the immune system by acting as an essential regulator of inflammation-related serum glycoproteins . Mrc1 deficient mice have no obvious phenotype other than elevated serum lysosomal enzymes related to slower clearance of serum glycoproteins, including the acid hydrolases , .
The CUBN gene encoding cubilin on the other hand has a well established role in cobalamin uptake. Mutations in this gene have been shown to cause IGS, also termed megaloblastic anemia 1 in humans (MGA1, OMIM #261100) . In contrast to MRC1, CUBN is thus an excellent functional candidate gene for the hereditary cobalamin malabsorption disorder observed in Border Collies. We therefore conclude that the CUBN:c.8392delC variant is the most likely causative defect for the phenotype, which we propose to call IGS in analogy to the human disease. According to our knowledge, these are the first dogs with a characterized molecular defect in the CUBN gene. Together with AMN mutant Australian Shepherd Dogs and Giant Schnauzers  the CUBN mutant Border Collies now complete the repertoire of molecular characterized dog models for IGS in humans.
The carrier frequency of dogs being heterozygous for the CUBN:c.8392delC variant in a cohort of nearly 200 randomly selected Border Collies is relatively low at 6.2%.
This study highlights the power of complete genome re-sequencing. Using this approach we were able to quickly identify the most likely causative variant for IGS in Border Collies. This variant could also have been obtained by a conventional candidate gene approach. In the case of IGS however, the two known candidate genes would have comprised a total of 79 exons, and the individual design of PCR primers and traditional workflow of PCR-amplifying each exon followed by Sanger sequencing would have required about the same amount of time and money in our laboratory as the whole genome re-sequencing experiment. In contrast to data from a conventional and more limited candidate gene approach, our analysis has also revealed the unexpected finding of a nonsense mutation in the MRC1 gene. The MRC1 variant is located 849 kb away from the CUBN frameshift variant on dog chromosome 2. Both variants appear to segregate only in Border Collies and have thus most likely arisen within the last 200 years. Unfortunately, the MRC1 and CUBN variants were in perfect linkage disequilibrium in all available dogs of our study, so that we could not disentangle the functional effects of each variant separately. Nonetheless, the seven IGS affected Border Collies did not show any obvious differences in their clinical phenotype with respect to other dogs with primary cobalamin absorption disorders. In particular they showed no signs of immunodeficiency or exaggerated inflammatory reactions (data not shown). It therefore appears that a spontaneous inactivation of the MRC1 gene in dogs does not result in any obvious clinical phenotype, similar to what has been observed in Mrc1 knock out mice .
In conclusion the identification of a candidate causative mutation for IGS in Border Collies provides the first dog model for IGS with a molecular characterized CUBN defect. Our findings will allow the development of a genetic test and eradication of IGS from the privately owned Border Collie breeding population.
Materials and Methods
All animal experiments were performed according to the local regulations. The dogs in this study were examined with the consent of their owners. The study was approved by the “Cantonal Committee For Animal Experiments” (Canton of Bern; permits 22/07 and 23/10).
We used 7 Border Collie cases, which could be unambiguously phenotyped based on small growth, poor BCS, undetectable serum cobalamin concentrations, methylmalonic aciduria, homocysteinemia (4/7) and complete clinical response to exclusive parenteral cobalamin supplementation. These were all affected dogs that we could obtain for the study and thus represent a convenience sample. Two of the cases were full-siblings. The 7 control Border Collies for the GWAS were judged to be healthy based on unremarkable history and physical examination, as well as normal normal results of CBC, serum biochemistry, urinalysis, serum cobalamin, urinary methylmalonic acid, and plasma homocysteine concentration. We classified additional dogs as controls based on owner-reported unremarkable histories. The complete cohort for this study consisted of 200 Border Collies and 357 dogs of diverse other breeds (Table S3). We collected EDTA blood samples from all dogs.
DNA Samples and SNP Genotyping
We isolated genomic DNA samples from EDTA blood with the Nucleon Bacc2 kit (GE Healthcare). Genotyping was done on illumina canine_HD chips containing 173,662 SNP markers at the NCCR Genomics Platform of the University of Geneva. Genotypes were stored in a BC/Gene database version 3.5 (BC/Platforms).
Genome-wide Association Study (GWAS) and Homozygosity Mapping
We used PLINK v1.07  to perform genome-wide association analyses (GWAS). We removed markers and individuals with call rates <90% from the analysis. We also removed markers with minor allele frequency (MAF) <5% and markers strongly deviating from Hardy-Weinberg equilibrium (p<10−5). We performed an allelic association study using the –assoc command of PLINK. We also used PLINK to search for extended intervals of homozygosity with shared alleles as described previously .
Raw p-values in the GWAS are based on χ2 tests of the allele frequency in cases vs the allele frequency in controls for each marker. After the filtering procedures described above, we had 112,323 markers left for the final analysis. In order to correct for the multiple testing situation, we determined an empirical significance threshold by performing 100,000 permutations of the dataset with arbitrarily assigned phenotypes.
We used the dog CanFam 3 genome assembly derived from a Boxer as reference genome sequence. All numbering within the canine CUBN gene corresponds to the accessions NM_001003148.1 (mRNA) and NP_001003148.1 (protein).
Whole Genome Sequencing of an Affected Border Collie
We prepared a fragment library with 300 bp insert size and collected one lane of illumina HiSeq2000 paired-end reads (2×100 bp). We obtained a total of 125,457,731 paired-end reads or roughly 10× coverage. We mapped the reads to the dog reference genome with the Burrows-Wheeler Aligner (BWA) version 0.5.9-r16  with default settings and obtained 243,130,060 uniquely mapping reads. After sorting the mapped reads by the coordinates of the sequence with Picard tools, we labeled the PCR duplicates also with Picard tools (http://sourceforge.net/projects/picard/). We used the Genome Analysis Tool Kit (GATK version 0591, ) to perform local realignment and to produce a cleaned BAM file. Variants calls were then made with the unified genotyper module of GATK. Variant data for each sample were obtained in variant call format (version 4.0) as raw calls for all samples and sites flagged using the variant filtration module of GATK. Variant calls that failed to pass the following filters were labeled accordingly in the call set: (i) Hard to Validate MQ0≥4 & ((MQ0/(1.0 * DP)) >0.1); (ii) strand bias (low Quality scores) QUAL <30.0 || (Quality by depth) QD <5.0 || (homopolymer runs ) HRun >5 || (strand bias) SB >0.00; (iii) SNP cluster window size 10. The snpEFF software  together with the CanFam 3.1 annotation was used to predict the functional effects of detected variants.
We used Sanger sequencing to confirm the illumina sequencing results and to perform targeted genotyping for selected variants. For these experiments we amplified PCR products using AmpliTaqGold360Mastermix (Applied Biosystems). PCR products were directly sequenced on an ABI 3730 capillary sequencer (Applied Biosystems) after treatment with exonuclease I and shrimp alkaline phosphatase. We analyzed the sequence data with Sequencher 4.9 (GeneCodes).
Genes in the 3.53 Mb critical interval on CFA 2.
Non-synonymous and associated variants in the 3.53 Mb critical interval on CFA 2.
The authors are grateful to referring veterinarians and to all dog owners and breeders who donated blood samples and shared pedigree data of their dogs. We thank Brigitta Colomb and Muriel Fragnière for expert technical assistance, the NCCR Genomics Platform in Geneva for SNP genotyping, and the Next Generation Sequencing Platform of the University of Bern for performing the whole genome sequencing experiment.
Conceived and designed the experiments: TL PHK. Performed the experiments: MO-L VJ CD. Analyzed the data: MO-L VJ TL. Contributed reagents/materials/analysis tools: SL BG PHK. Wrote the paper: MO-L TL PHK.
- 1. Nielsen MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK (2012) Vitamin B12 transport from food to the body’s cells–a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol 9: 345–354.
- 2. Fyfe JC, Madsen M, Højrup P, Christensen EI, Tanner SM, et al. (2004) The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood 103: 1573–1579.
- 3. Andersen CB, Madsen M, Storm T, Moestrup SK, Andersen GR (2010) Structural basis for receptor recognition of vitamin-B12-intrinsic factor complexes. Nature 464: 445–448.
- 4. Aminoff M, Carter JE, Chadwick RB, Johnson C, Gräsbeck R, et al. (1999) Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. Nat Genet 21: 309–313.
- 5. Tanner SM, Aminoff M, Wright FA, Liyanarachchi S, Kuronen M, et al. (2003) Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary megaloblastic anemia. Nat Genet 33: 426–429.
- 6. Gräsbeck R (2006) Imerslund-Gräsbeck syndrome (selective vitamin B12 malabsorption with proteinuria). Orphanet J Rare Dis 1: 17.
- 7. He Q, Madsen M, Kilkenney A, Gregory B, Christensen EI, et al. (2005) Amnionless function is required for cubilin brush-border expression and intrinsic factor-cobalamin (vitamin B12) absorption in vivo. Blood 106: 1447–1453.
- 8. Fordyce HH, Callan MB, Giger U (2000) Persistent cobalamin deficiency causing failure to thrive in a juvenile beagle. J Small Anim Pract 41: 407–410.
- 9. Outerbridge CA, Myers SL, Giger U (1996) Hereditary cobalamin deficiency in Border Collies. J Vet Intern Med 10: 169.
- 10. Morgan LW, McConnell J (1999) Cobalamin deficiency associated with erythroblastic anemia and methylmalonic aciduria in a border collie. J Am Anim Hosp Assoc 35: 392–395.
- 11. Battersby IA, Giger U, Hall EJ (2005) Hyperammonaemic encephalopathy secondary to selective cobalamin deficiency in a juvenile Border collie. J Small Anim Pract 46: 339–344.
- 12. Lutz S, Sewell AC, Reusch CE, Kook PH (2013) Clinical and laboratory findings in young Border Collies with presumed hereditary juvenile cobalamin deficiency. J Am Anim Hosp Assoc, DOI:10.5326/JAAHA-MS-5867.
- 13. Fyfe JC, Giger U, Hall CA, Jezyk PF, Klumpp SA, et al. (1991) Inherited selective intestinal cobalamin malabsorption and cobalamin deficiency in dogs. Pediatr Res 29: 24–31.
- 14. Bishop MA, Xenoulis PG, Berghoff N, Grützner N, Suchodolski JS, et al. (2012) Partial characterization of cobalamin deficiency in Chinese Shar Peis. Vet J 191: 41–55.
- 15. Lutz S, Sewell AC, Bigler B, Riond B, Reusch CE, et al. (2012) Serum cobalamin, urine methylmalonic acid, and plasma total homocysteine concentrations in Border Collies and dogs of other breeds. Am J Vet Res 73: 1194–1199.
- 16. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, et al. (2002) Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295: 1898–1901.
- 17. Sly WS, Vogler C, Grubb JH, Levy B, Galvin N, et al. (2006) Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci U S A 103: 15172–15177.
- 18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
- 19. Drögemüller C, Becker D, Brunner A, Haase B, Kircher P, et al. (2009) A missense mutation in the SERPINH1 gene in Dachshunds with osteogenesis imperfecta. PLoS Genet 5: e1000579.
- 20. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.
- 21. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297–1303.
- 22. Cingolani P, Platts A, Coon M, Nguyen T, Wang L, et al. (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6: 80–92.